This strategy has been further applied to drive to lung cancer cells the functional domain of Discoidin domain receptor 2 (DDR2), a collagen-induced receptor tyrosine kinase that is emerged as a novel therapeutic target in lung cancer. This evidence concerns the gene DDR2 and lung carcinoma.